April 30th 2024
The majority of the US adult population meets criteria for subclinical CKM syndrome indicating "an urgent need for population-wide risk reduction measures."
Michael A. Weber, MD, on aprocitentan approval: A new approach to managing hypertension
March 21st 2024Michael A. Weber, MD, an investigator in the PRECISION study, discusses the newly FDA approved drug aprocitentan (Tryvio), and its promise for helping patients with treatment-resistant hypertension.